Margolis AM, Heverling H, Pham PA, Stolbach A
Serious Adverse Events and Contraindications Serious side effects (hospitalization-level events) were rare with both drugs
Researchers are developing metabolic therapies that act on several hormone receptors, such as GLP-1, GIP and glucagon
Fritzen, R., Davies, A., Veenhuizen, M., Campbell, M., Pitt, S
It took about a year to assemble the funding for a one-year pilot program, identify a pharmacy to compound the semaglutide the active ingredient in some of the more costly, name-brand GLP-1s and find a doctor willing to prescribe the drug for off-label use to uninsured participants
FDA Actions: Targeting Illegal Operations, Not Licensed Pharmacies In 2023 and 2024, the FDA issued warning letters and seized products from multiple unlicensed entities falsely marketing compounded GLP-1 medications